Cell vaccines articles from across Nature Portfolio

Here the authors report an exploratory analysis of a clinical trial that tested different influenza virus vaccination platforms. The results show that multiple seasons of recombinant or cell-based influenza vaccinations may be needed to redirect antibody responses away from immune memory to egg-adapted epitopes and refocus on epitopes on the circulating viruses.

Whole autologous tumor cell vaccine (TCV) has been proposed as a tool for cancer immunotherapy. Here the authors describe the design of a TCV platform based on photothermal nanoparticle-loaded tumor cells, triggering NIR laser irradiation induced anti-tumor immune responses at the vaccination site.

For cell therapies to transition from promises to products, increased efforts need to be put into the identification of the factors and biological mechanisms that affect safety and efficacy, and into the design of cost-effective methods for the harvesting, expansion, manipulation and purification of the cells.

Potent dendritic-cell cancer vaccines could be used to induce functional antitumour immunity without off-target toxicity.